Tailored, skilled care is necessary when navigating a brain tumor or brain cancer. At AHN, our expert neurosurgeons are at the forefront of using advanced technologies that target a variety of tumors affecting the brain. The care you receive at AHN is customized to your needs and delivered with compassion and precision. The state-of-the-art treatment available for patients at AHN includes a broad array of options for the diverse patient population we serve.
An option for many patients with brain tumors is GammaTile® brachytherapy. GammaTile therapy is an FDA-approved, surgically targeted radiation therapy (STaRT) for malignant brain tumors (such as glioblastoma and brain metastasis) and recurrent benign brain tumors. It is designed to eliminate microscopic residual tumor cells after surgical removal of a brain tumor.
GammaTile therapy is a targeted radiation treatment. It involves placing small, bioresorbable collagen tiles, each containing four seeds that emit low-dose radiation, directly at the site of the tumor after it has been surgically removed. The goal is to destroy remaining cancer cells while minimizing damage to healthy brain tissue.
GammaTile may eliminate the need for further radiation treatments after surgery — letting patients receive radiation therapy while they are recovering from surgery. The decision to treat a patient with GammaTile requires a multidisciplinary team of neurosurgeons, radiation oncologists, neuro-oncologists, and radiation physicists. At AHN, we have created a Multidisciplinary Brain Tumor Clinic to improve patient experience and offer cutting-edge technology such as GammaTile. At AHN, our approach to brain tumor care has led to AHN being recognized as a GammaTile Center of Excellence in 2025.
Our highly experienced team of neuro-oncologists (brain cancer specialists) and neurosurgeons (brain surgeons) performs treatments that are only available at the very best hospitals in the country. By choosing AHN for your care, you will find:
The GammaTile procedure is performed in a hospital setting, specifically within an operating room. This is because it is a surgical procedure that involves removing the tumor and then implanting the GammaTiles. The GammaTile implantation itself is performed during the same surgical procedure as the tumor removal. The time for the entire surgery (tumor removal plus GammaTile placement) will vary depending on the size, location, and complexity of the tumor. However, the placement of the GammaTiles is a relatively quick step at the end of the tumor resection (removal).
To prepare for the surgery, your AHN surgical and oncology teams will give you specific instructions and reviewing everything with you, so you can get your questions answered and feel confident in the plan. Overall, most patients will be asked to arrive at the hospital several hours before surgery to begin preparations. A GammaTile procedure often includes:
After the surgery, you will be moved into recovery where you will be closely monitored as you wake up from anesthesia. There may be some pain or discomfort, but that will be managed with medication. Your care team will watch closely for any neurological changes or complications, and your hospital stay will depend on your recovery. Most patients require several days of inpatient care.
The GammaTile aims to minimize severe side effects for those dealing with brain tumors. However, there are some postoperative side effects that some patients experience. Most side effects that patients experience are related to the surgical procedure, rather than GammaTile placement. These can include:
Sometimes, people will experience side effects from the GammaTile radiation. The localized, low-dose radiation from GammaTile is designed to reduce the severity of radiation-related side effects compared to external beam radiation, but they can still occur. These can include:
These side effects are rare, but it’s important for patients to be aware of the risks.
GammaTile is a state-of-the-art device that works to deliver targeted radiation to those dealing with brain tumors. AHN is committed to providing our patients with advanced treatment options. Your care team is available to answer any and all questions you may have about this procedure. We’ve included some basic questions that many of our patients have and hope you can use these answers to build your confidence in the procedure.
Yes, GammaTile therapy is FDA-approved. It received FDA 510(k) clearance in July 2018 for treating newly diagnosed malignant brain tumors and recurrent brain tumors. In January 2020, its indications were expanded to include all types of recurrent brain tumors and newly diagnosed malignant brain tumors. This means the FDA has determined that GammaTile is safe and effective for its intended use.
The success rate for GammaTile therapy is typically measured by its ability to control tumor growth at the surgical site (local control) and improve overall survival. Studies on the procedure have delivered favorable results:
GammaTile is a surgical adjunct that provides targeted internal radiation after tumor removal, while Gamma Knife is a nonsurgical external radiation technique used to treat intact brain lesions with high precision. They can sometimes be used in sequence or as complementary treatments, depending on the patient's specific condition and treatment plan.
To schedule an appointment or learn more about AHN neuroscience services, call 412-359-6200 in Pittsburgh or 814-452-7575 in Erie.